Clinical Trials Logo

Hepatic Veno-Occlusive Disease clinical trials

View clinical trials related to Hepatic Veno-Occlusive Disease.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT00263978 No longer available - Liver Diseases Clinical Trials

Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

Start date: November 2005
Phase: N/A
Study type: Expanded Access

Severe veno-occlusive disease (VOD) of the liver is a life threatening complication of blood and marrow transplantation. Treatment with currently available (Food and Drug Administration [FDA] approved) agents fails in most cases. Recently conducted clinical studies indicate that patients benefit from defibrotide, a non-FDA approved agent. This protocol has been developed not with a research intent, but rather to ensure that defibrotide is used by the blood and marrow transplant programs at Children's Healthcare of Atlanta and at Emory University in a safe, effective and ethical manner.

NCT ID: NCT00143546 No longer available - Clinical trials for Hepatic Veno-occlusive Disease

Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

Start date: November 2003
Phase: N/A
Study type: Expanded Access

Veno-occlusive disease (VOD) of the liver is a significant complication for some patients undergoing hematopoietic stem cell transplantation. This disease is thought to be a toxicity secondary to chemotherapy or radiation-induced damage to the epithelial cells of the blood vessels in the liver. VOD is categorized as mild, moderate or severe. Historically, there has been no method to treat the disease. Recently, however, there have been investigations into the use of a new agent called defibrotide. The primary purpose of this protocol is to provide defibrotide to patients with severe VOD. Because this drug has not been approved by the FDA, use of this medication under the auspices of this IND treatment plan is for compassionate use only.